Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.
Innovation required in risk assessment of nanoparticles The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.
Outbreak of avian influenza A (H5N8) in Dutch poultry In November 2014 avian ‘flu has been detected on poultry farms in the Netherlands.
RIVM film about nanomaterials RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.
No more complementary vaccinations against measles for children aged six months The measles epidemic, the first case of which occurred in the Netherlands in May 2013, is coming to an end.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.
Nanotechnology in the fight against cancer Nanotechnology offers improved options for the diagnosis and treatment of cancer.
Teenage girl dies after measles infection Last weekend, a 17-year-old girl from the province of Zeeland (The Netherlands) has died of complications after a measles infection. She was not vaccinated against the disease.
Is screening for sexually transmitted infections as part of HIV care cost-effective in the Netherlands? Routine screening for anorectal chlamydia among HIV-positive men who have sex with men (MSM) could avert further spread of chlamydia and HIV in the total MSM population.
Regional differences in testing rates underestimate incidence of LGV epidemic Until 2003, Lymphogranuloma venereum (LGV), an aggressive form of chlamydia, was considered to be a rare tropical disease, endemic to Africa, Asia and the Caribbean.